Series: Landmark Trials in Endocrinology & Metabolism | Study #29
Category: Lipids & Statins · Cardiovascular Outcomes | Design: Multicentre, double-blind, placebo-controlled RCT | n: 4,444 | Follow-up: 5.4 years (median)
📋 Summary
Authors: Scandinavian Simvastatin Survival Study Group
Journal: Lancet 1994;344:1383–1389 | PMID: 7968073
The 4S trial enrolled 4,444 patients with angina pectoris or previous myocardial infarction and serum cholesterol of 5.5–8.0 mmol/L on a lipid-lowering diet, randomised to double-blind treatment with simvastatin or placebo. Over the 5.4-year median follow-up, simvastatin produced mean changes from baseline in total cholesterol (−25%), LDL-cholesterol (−35%), and HDL-cholesterol (+8%), with few adverse effects. All-cause mortality occurred in 256 patients (12%) in the placebo group compared with 182 (8%) in the simvastatin group (relative risk of death in the simvastatin group 0.70; 95% CI 0.58 to 0.85; p=0.0003). Coronary deaths were 189 in the placebo group and 111 in the simvastatin group (relative risk 0.58; 0.46 to 0.73). Non-cardiovascular deaths were 49 and 46 respectively, confirming no excess non-cardiac mortality with statin therapy. Major coronary events (composite of coronary death or non-fatal MI) occurred in 622 placebo patients (28%) versus 431 simvastatin patients (19%; relative risk 0.66; 0.59 to 0.75; p<0.00001). The 6-year survival probability was 87.6% in the placebo group versus 91.3% in the simvastatin group. Myocardial revascularisation procedures were reduced by 37%.
📊 Key Findings
<figure class="wp-block-table">
| Outcome | Simvastatin | Placebo | Effect Size |
|---|---|---|---|
| All-cause mortality | 8% (182) | 12% (256) | RR 0.70 (0.58–0.85) · p=0.0003 · 30% RRR |
| Coronary death | 111 | 189 | RR 0.58 (0.46–0.73) · 42% RRR |
| Major coronary events (death or MI) | 19% (431) | 28% (622) | RR 0.66 (0.59–0.75) · p<0.00001 · 34% RRR |
| Myocardial revascularisation | — | — | 37% reduction · p<0.00001 |
| Non-CV deaths | 46 | 49 | No excess · Safety confirmed |
| LDL-cholesterol change | −35% | — | Primary lipid driver |
💬 Expert Commentary
The 4S trial resolved decades of uncertainty about whether pharmacological cholesterol lowering actually reduces mortality in patients with coronary heart disease. Prior to 4S, the lipid hypothesis — that elevated LDL-cholesterol causes coronary heart disease and that reducing it should therefore prevent coronary events — was well supported by epidemiology and animal models, and earlier drug trials had demonstrated reductions in non-fatal MI. However, concerns about whether cholesterol lowering might increase non-cardiovascular mortality (a signal suggested by some earlier fibrate and gemfibrozil trials) had created hesitancy. The 4S result was definitive: all-cause mortality was reduced by 30% with simvastatin, coronary deaths by 42%, and crucially, non-cardiovascular deaths were no more frequent in the statin group than in the placebo group. The safety finding was as important as the efficacy finding, and it removed the primary clinical obstacle to broad adoption of statin therapy in secondary prevention.
The 4S trial enrolled a high-risk secondary prevention population, and its NNT must be understood in that context. Over 5.4 years, approximately 8 patients needed to be treated with simvastatin to prevent one death — an NNT that is among the most favourable in preventive cardiology and compares very favourably with other accepted cardiovascular interventions. The 4S result triggered a rapid global adoption of statin therapy in secondary prevention and stimulated the primary prevention trials (WOSCOPS, HPS, CARDS) that followed. It also initiated the decades-long process of lowering LDL targets, from the initial goals of below 3.0 mmol/L in secondary prevention to the current very-high-risk targets of below 1.4 mmol/L in contemporary guidelines, as each subsequent trial demonstrated that lower achieved LDL correlates with greater absolute cardiovascular risk reduction.
Limitations: The population was enrolled on specific cholesterol entry criteria (5.5–8.0 mmol/L), limiting direct generalisation to patients with lower baseline cholesterol. The trial was conducted in a predominantly Scandinavian population. The study was funded by Merck Sharp and Dohme.
<blockquote class="wp-block-quote">
🔑 BOTTOM LINE
The 4S trial demonstrated that simvastatin reduces all-cause mortality by 30%, coronary death by 42%, and major coronary events by 34% in patients with established coronary heart disease, with no excess non-cardiovascular mortality, resolving the longstanding safety debate and establishing statin therapy as the cornerstone of secondary cardiovascular prevention worldwide.
⭐ Clinical Impact Rating: ●●●●● Practice-defining
Next in the series: Study #30 WOSCOPS: Pravastatin for Primary Prevention of Coronary Heart Disease in Men with Hypercholesterolaemia
